A convenient and sensitive enzyme-linked immunosorbent assay (ELISA) for the STb heat-stable enterotoxin of Escherichia coli was developed and used to quantify STb production by strains with a high level of expression. Based on an antigenic profile of the secreted form of STb, a synthetic peptide (STb3-27) spanning the major predicted epitope was synthesized, coupled to keyhole limpet hemocyanin, and used to immunize rabbits. Anti-STb3-27 antibodies were affinity purified on a synthetic peptide-Sepharose 4B column and used in a direct-binding STb ELISA. Based on a highly purified form of toxin as a standard, the ELISA detected as little as 1 to 2 ng of STb from crude culture filtrates. ELISA data revealed that natural STb-producing strains elaborate little STb in defined-medium cultures relative to that elaborated by a recombinant strain harboring a cloned copy of the estB gene. Replacement of the endogenous STb promoter with any of several highly active promoters, including a bacteriophage T7 promoter, a 13-galactosidase promoter, and a tryptophan-13-galactosidase hybrid (tac) promoter, increased the yield of STb 10-to 20-fold over levels obtained by an E. coli strain harboring the recombinant estB gene. The high level of STb antigen detected by the ELISA correlated with intestinal secretory activity. The combination of a convenient assay and effective hyperproduction of STb will serve as a basis for a large-scale toxin purification strategy.
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Enterotoxigenic Escherichia coli (ETEC) causes serious diarrheal disease in humans and domestic animals by the production of protein enterotoxins. One class of ETEC toxins, the heat-labile enterotoxins (LTI and LTII), are structurally and functionally related to cholera toxin and appear to mediate secretion by similar mechanisms (4, 5, 11, 14) . The heat-stable enterotoxins produced by ETEC, STa and STb, are distinct from the heat-labile enterotoxins in structure, antigenicity, and biological activity. STa and STb share some interesting features, in that the estA and estB genes are both integral parts of separate bacterial transposons (16, 19, 26, 27) , and the encoded products are cysteine-rich (20, 23, 27) . STb and STa are often produced by the same ETEC isolate from swine, and STb appears to be a significant contributor to swine colibacillosis, in that the estB gene is the most common toxin gene found in association with ETEC of diseased swine (22) . Despite its prevalence in swine, the STb gene is uncommon in ETEC of human origin, and STb does not appear to be a cause of human diarrheal disease (7, 33) .
Despite similarities in heat stability and association with transposons, STa and STb appear to be totally distinct toxins. STa is an 18-or 19-amino-acid peptide that is devoid of basic residues and contains 6 cysteine residues with no free sulfhydryl groups (6, 29, 31) . Export of STa to the surrounding medium by E. coli proceeds via a two-step process, the final step of which occurs on the extracellular side of the outer membrane (24) . In the gut, STa binds to a unique receptor located in the brush border membrane (9, 10) and activates particulate guanylate cyclase in intestinal * Corresponding author. epithelial cells (12) . Accumulation of cyclic GMP in the gut mucosa correlates with the resulting secretory response (8) . In contrast to STa, relatively little information concerning the biochemistry and mode of STb action is available; however, the gene encoding STb has been cloned and sequenced (20, 23) . Furthermore, the export of STb proceeds via a single processing step (18) distinct from that of STa (24) . The secreted form of STb is a 48-amino-acid, lysine-rich peptide (18) . Therefore, STa and STb are totally distinct toxins with very different apparant biochemical properties. Although the intestinal secretory action of STb is poorly understood, the available data indicate that STb induces gut fluid secretion by a previously uncharacterized mechanism that is apparently independent of changes in cyclic nucleotide levels (17, 32 (21) . The plasmids pBR322 (1) and pUC18 (35) were obtained from BRL Life Technologies, Inc., and pDR540 (25) , which was used as a source of the trp-lac (tac) promoter (25) , was obtained from Pharmacia LKB Biotechnology, Inc., Piscataway, N.J. A bacteriophage T7-promoted STb expression plasmid, pUD1, was constructed in our laboratory and has been described elsewhere (18) . We obtained pCHL6 (20) , an STb-encoding recombinant derivative of pBR322, from C. H. Lee (34) .
Generation of STb-specific affinity-purified rabbit antibody. (i) Synthesis of STb3-27 and coupling to KLH. A synthetic peptide representing residues 3 to 27 of processed STb (18) (codons 26 to 50 of a previously reported sequence [20, 23] ) was synthesized at the Synthesis Core Facility Laboratory, University of Texas Medical Branch, on a Biosearch 9600 peptide synthesizer (MilliGen/Biosearch, Novato, Calif.). For immunogen, synthetic peptide was coupled to keyhole limpet hemocyanin (KLH; Calbiochem Corp., La Jolla, Calif.) by using maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Pierce Chemical Co., Rockford, Ill.) as described below. To 5 mg of KLH dissolved in 0.25 ml of phosphate buffer (0.05 M; pH 7.5) was added 0.4 mg of MBS (50X molar excess of MBS, assuming an average molecular weight of 200,000 for KLH) dissolved in 0.25 ml of dimethyl sulfoxide. The reaction was allowed to proceed for 30 min at room temperature. Unreacted MBS was removed by Sephadex G-50 (Pharmacia LKB Biotechnology, Inc.) gel filtration chromatography. A 50x molar excess of synthetic peptide (3.6 mg), which was dissolved in 0.1 ml of phosphate-buffered saline (PBS), was added to the MBS-activated KLH. In addition, 2 x 106 cpm of 1251-labeled peptide (described below) was added as an indicator of coupling efficiency. Peptide and MBS-activated KLH were mixed at room temperature for 2 h and then dialyzed overnight against 0.05 M phosphate buffer. A portion of the dialyzed preparation was assayed for peptide by liquid scintillation counting. Under the conditions described above, greater than 70% of the added peptide was routinely coupled to KLH.
(ii) 1251 labeling of STb3-27. Synthetic peptide was radiolabeled with 1251 by using Iodobeads (Pierce Chemical Co.) as described by the manufacturer. The reaction mixture consisted of 1 ,ug of synthetic peptide, 1 mCi of carrier-free '25NaI (ICN Biomedicals, Inc., Costa Mesa, Calif.), and two iodobeads in a total volume of 0.25 ml. The reaction was started by the addition of beads and was allowed to proceed at room temperature for 20 min. Unincorporated 1251 was removed from the peptide fraction by BioGel P2 (Bio-Rad Laboratories, Richmond, Calif.) gel filtration chromatography. Radioactivity was determined by gamma-radiation spectroscopy. Void volume fractions containing radiolabeled peptide were collected and saved for incorporation into the coupling reactions described above.
(iii) Immunization of rabbits with STb3-27-KLH. Female New Zealand White rabbits were immunized with the STbpeptide KLH conjugate by the following regimen. Each rabbit received 1 mg (peptide equivalent based on coupling efficiency to KLH) of peptide KLH conjugate in Freund complete adjuvent. One half of the immunogen was given as approximately eight subcutaneous injections along the back; the other half was administered by intramuscular injection in a hind quarter. Four weeks following the primary immunization, rabbits were immunized with the same dose of immunogen emulsified with Freund incomplete adjuvent. A second booster immunization, which was identical to the first one, was given 1 month following the first booster immunization. Rabbits were bled, and sera were collected 1 week following the administration of the second booster immunization. Whole serum was fractionated by ammonium sulfate precipitation (33% saturation) followed by dialysis. The dialyzed immunoglobulin G (IgG)-enriched fraction was then filtered through a synthetic peptide-Sepharose 6B column prepared as described below. The eluted antibody fraction was assayed for protein by the method of Bradford (3) by using protein dye reagent obtained from Pierce Chemical Co. Aliquots were frozen (-200C) until they were used in the ELISA method described below.
(iv) Preparation of affinity-purified anti-STb3-27 antibody.
The STb3-27 peptide-Sepharose 6B column was prepared by reacting purified synthetic peptide with hydrated and washed epoxy-activated Sepharose 6B (Pharmacia LKB Biotechnol- (15) . The result of the antigen profile (Fig. 1) possible, we synthesized the peptide QSNKKDLCEHYRQ IAKESCKKGFLG, which corresponded to STb3-27 (STb codons 26 to 50). The peptide was coupled to KLH and was used to generate an immune response to native STb, as described in Materials and Methods.
STb ELISA. The antibody response to KLH-coupled synthetic peptide was determined by testing dilutions of affinity-purified antibody against bound peptide in a direct ELISA. The affinity-purified antibody (5 mg/ml) still exhibited a strong reaction with bound peptide at a dilution of 1:25,000 (or 200 u.glml) (Fig. 2A) . The ELISA reaction with bound KLH was negligible (data not shown). The specificity and sensitivity of the assay for STb was tested by performing the ELISA, at antibody saturation (1:500), on a preparation of highly purified STb (Whipp, unpublished data). The data (Fig. 2B ) demonstrated that the peptide-specific antibody detected as little as 2.5 ng of STb based on first-order regression analysis of the curve and an arbitrary absorbance of 0.5. The STb3-27 antibody did not cross-react with E. coli STa (data not shown).
Alternate promoter hyperexpression of STb. In a previous study, Spandau and Lee (28) demonstrated that transcription of STb is controlled by a relatively weak constitutive promoter. In an attempt to overproduce STb, we replaced the endogenous STb promoter with promoters known to be highly active in E. coli. The expression plasmids (Fig. 3) were transferred to E. coli hosts and tested for their ability to express STb in defined-medium cultures. ELISA data on the production of STb by E. coli strains which harbored the three expression constructs and pCHL6 (the cloned copy of STb bearing its native promoter) indicated that a significant improvement in the level of STb produced by pCHL6 was attained with all three expression constructs (Fig. 4) . All three of the alternate promoter systems yielded filtrates with significantly more STb than pCHL6 (Fig. 4) . By performing a first-order regression on the data shown in Fig. 4 and arbitrarily assigning an absorbance of 0.5 as a reference point, it was revealed that the titer for STb from the pCHL6 culture was approximately 5 . Titers for cultures of the strains harboring pPD11, pUD1, and pPD21 were 52, 56, and 110, respectively. This represents increases over the amount of STb produced by the cloned estB gene of 10.4-, 11.2-, and 22-fold, respectively. These data were corroborated by pig intestinal loop results, which were consistent with the ELISA determinations (Table 1 ). In addition, it was observed that naturally occurring STb-producing isolates make very little STb (10 to 20% of that produced by pCHL6) in defined medium (data not shown).
Spandau and Lee (28) determined that the native STb promoter is weak relative to those of the lacZ or ompF operons. They suggested that the 2-log-unit reduction in STb (or reconstruction of) the recombinant strains, and furthermore, the results, as described, were difficult to interpret from a quantitative standpoint. In designing our assay, we hoped to provide the basic information necessary to reproduce the assay in almost any research laboratory. The major requirement for the assay reported here is the initial synthesis of a synthetic peptide that spans the major antigenic region of STb. Although we have no experimental evidence as yet, it is entirely likely that immunization with a significantly smaller peptide that spans the major predicted antigenic site (Lys-18 to Lys-23) would yield comparable results. This would greatly reduce the initial expense of reproducing the assay as described here. Although not shown here, the assay can be reproduced by using an IgG fraction of immune serum or even whole serum instead of affinity-purified antibody. The risk of spurious cross-reaction with other antigens in the assay mixture could present problems; however, the use of synthetic peptides for immunogens reduces the potential for the generation of cross-reactive antibodies, provided that the preimmune sera from selected animals are substantially free of cross-reactive antibodies to E. coli products. Affinity purification of the peptide-specific antibody does, however, provide a degree of specificity that otherwise cannot be attained without the use of monoclonal antibodies.
Aside from the obvious advantage of the ELISA described in this report over intestinal loop assays, there is a considerable degree of reproducibility that cannot be achieved with bioassays in general. Factors such as variability in animals, location of sample loops within the gut, and neighboring loop contents all contribute to variations in assay results that may translate to as much as three-to fivefold differences in toxin concentration. This variability complicates quantitative toxin assessments, and although the tendency is to regard these differences as being within the limits of precision, this level of variation is unacceptable when evaluating the efficiency of a purification regimen. Use of the ELISA described here will dramatically shorten the time and cost of STb purification protocols, and at the same time, it will permit assay of many more individual fractions. This undoubtedly will result in significant improvements in our schemes to produce large quantities of highly purified STb.
